Post-Conference Perspectives: Understanding HER2-Low Breast Cancer - Episode 3

Treating HER2-low Breast Cancer With Novel Antibody Drug Conjugates

,

Experts take a look at clinical data behind novel antibody drug conjugates and consider how they may impact the management of HER2-low breast cancer.

EP. 1: Current Landscape of HER2 Testing in Breast Cancer
EP. 2: Strategies in Identifying and Stratifying HER2 Status in Breast Cancer
Now Viewing
EP. 3: Treating HER2-low Breast Cancer With Novel Antibody Drug Conjugates
EP. 4: HER2-low Breast Cancer: Practical Applications of ADC Therapy

Related Content:

Post-Conference Perspectives: Understanding HER2-Low Breast CancerBreast Cancer
Genomic Predictors Inform the Evolving Role of Chemotherapy in Breast Cancer Management
BT7480 Shows Preliminary Activity in Nectin-4+, CD137+ Tumors
AE Profiles and Dosing Schedules Define the Role of CDK4/6 Inhibitors in HR+ Metastatic Breast Cancer